Mexico Diabetic Foot Ulcer Biologics Market Size & Outlook

The diabetic foot ulcer biologics market in Mexico is expected to reach a projected revenue of US$ 64.1 million by 2030. A compound annual growth rate of 5.6% is expected of Mexico diabetic foot ulcer biologics market from 2025 to 2030.
Revenue, 2024 (US$M)
$46.2
Forecast, 2030 (US$M)
$64.1
CAGR, 2025 - 2030
5.6%
Report Coverage
Mexico

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Mexico diabetic foot ulcer biologics market, 2018-2030 (US$M)

Mexico diabetic foot ulcer biologics market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Mexico diabetic foot ulcer biologics market highlights

  • The Mexico diabetic foot ulcer biologics market generated a revenue of USD 46.2 million in 2024 and is expected to reach USD 64.1 million by 2030.
  • The Mexico market is expected to grow at a CAGR of 5.6% from 2025 to 2030.
  • In terms of segment, skin substitutes was the largest revenue generating product in 2024.
  • Tissue-Engineered Products is the most lucrative product segment registering the fastest growth during the forecast period.


Diabetic foot ulcer biologics market data book summary

Market revenue in 2024USD 46.2 million
Market revenue in 2030USD 64.1 million
Growth rate5.6% (CAGR from 2025 to 2030)
Largest segmentSkin substitutes
Fastest growing segmentTissue-Engineered Products
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSkin Substitutes, Growth Factors, Tissue-Engineered Products
Key market players worldwideOrganogenesis Holdings Inc Class A, Tissue Regenix, BioTissue, Integra Lifesciences Holdings Corp, MiMedx Group Inc, ConvaTec Inc., Coloplast A/S ADR, Smith & Nephew PLC, Stedical Scientific, Zimmer Biomet Holdings Inc, Gunze


Other key industry trends

  • In terms of revenue, Mexico accounted for 2.3% of the global diabetic foot ulcer biologics market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. diabetic foot ulcer biologics market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 1,061.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Diabetic Foot Ulcer Biologics Market Companies

Name Profile # Employees HQ Website
Gunze View profile 5001-10000 Osaka, Osaka, Japan, Asia https://www.gunze.co.jp/
Stedical Scientific View profile - Carlsbad, California, United States, North America https://www.stedical.com/
ConvaTec Inc. View profile - - -
Tissue Regenix View profile 51-100 York, York, United Kingdom, Europe http://www.tissueregenix.com
BioTissue View profile 1-10 Genève, Geneve, Switzerland, Europe http://www.biotissue.ch
Organogenesis Holdings Inc Class A View profile 862 85 Dan Road, Canton, MA, United States, 02021 https://www.organogenesis.com
MiMedx Group Inc View profile 895 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062 https://www.mimedx.com
Smith & Nephew PLC View profile 18452 Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, United Kingdom, WD18 8YE https://www.smith-nephew.com
Coloplast A/S ADR View profile 15930 Holtedam 1-3, Humlebaek, Denmark, DK-3050 https://www.coloplast.com
Integra Lifesciences Holdings Corp View profile 3946 1100 Campus Road, Princeton, NJ, United States, 08540 https://www.integralife.com
Zimmer Biomet Holdings Inc View profile 18000 345 East Main Street, Warsaw, IN, United States, 46580 https://www.zimmerbiomet.com

Mexico diabetic foot ulcer biologics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetic foot ulcer biologics market will help companies and investors design strategic landscapes.


Skin substitutes was the largest segment with a revenue share of 53.9% in 2024. Horizon Databook has segmented the Mexico diabetic foot ulcer biologics market based on skin substitutes, growth factors, tissue-engineered products covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Mexico diabetic foot ulcer biologics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Mexico diabetic foot ulcer biologics market databook

  • Our clientele includes a mix of diabetic foot ulcer biologics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Mexico diabetic foot ulcer biologics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico diabetic foot ulcer biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Mexico diabetic foot ulcer biologics market size, by product, 2018-2030 (US$M)

Mexico Diabetic Foot Ulcer Biologics Market Outlook Share, 2024 & 2030 (US$M)

Mexico diabetic foot ulcer biologics market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online